Highly efficient new generation synthetic RNA-replicon based vaccine

Projektinformationen

REPLIXCEL

ID Finanzhilfevereinbarung: 251420

Abgeschlossenes Projekt

Startdatum 1 April 2010

Enddatum 31 März 2014

Finanziert unter

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 2 591 172,00

EU-Beitrag € 2 591 172,00

Koordiniert durch

THE UNIVERSITY OF MANCHESTER
United Kingdom

Ziel

The project seeks to create a novel, efficacious vaccine against influenza virus; a new type of synthetic vaccine readily adaptable to meet whichever influenza virus subtype may arise. A new generation of RNA-replicon technology will be employed combined with nanoparticles and innovative adjuvants for targeting of dendritic cells and efficient antigen expression. The consortium comprises two SMEs and two academic institutions each having unique and patented expertise such as replicon technology, nanoparticle technology, adjuvant chemistry, and surface modification chemistry to attach targeting moieties. As a highly interdisciplinary project, extensive exchange of knowledge between the project partners will be required in particular between product focused SMEs (nanoparticles, adjuvants) and technology excellence of academic institutions (replicon technology, surface modification chemistry).

Wissenschaftliches Gebiet

• natural sciences › biological sciences › microbiology › virology
• medical and health sciences › health sciences › infectious diseases › RNA viruses › influenza
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines
• engineering and technology › nanotechnology › nano-materials

Programm/Programme

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Thema/Themen

• FP7-PEOPLE-2009-IAPP - Marie Curie Action: "Industry-Academia Partnerships and Pathways"

Aufforderung zur Vorschlagseinreichung

FP7-PEOPLE-2009-IAPP
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Koordinator

THE UNIVERSITY OF MANCHESTER

Kontakt Verwaltung

Liz Fay (Ms.)

• EU-Beitrag: € 799 522,00
• Adresse: OXFORD ROAD ; M13 9PL Manchester ; Vereinigtes Königreich
• Region: North West (England) › Greater Manchester › Manchester
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: Keine Daten

Beteiligte (3)

EIDGENOESSISCHES DEPARTEMENT FUER WIRTSCHAFT, BILDUNG UND FORSCHUNG

Schweiz

Kontakt Verwaltung

Kenneth Charles Mccullough (Dr.)

• EU-Beitrag: € 739 085,00
• Adresse: Bundeshaus Ost ; 3003 Bern
• Region: Schweiz/Suisse/Svizzera › Espace Mittelland › Bern / Berne
• Aktivitätstyp: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
• Gesamtkosten: Keine Daten

EMC MICROCOLLECTIONS GMBH

Deutschland

Kontakt Verwaltung

Renate Spohn (Dr.)

• EU-Beitrag: € 303 725,00
• Adresse: Sindelfinger Str. 3 ; 72070 Tuebingen
• Region: Baden-Württemberg › Tübingen › Tübingen, Landkreis
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: Keine Daten

Medipol SA

Beteiligung beendet

Schweiz

Kontakt Verwaltung

Carsten Laue (Dr.)

• EU-Beitrag: € 748 840,00
• Adresse: Parc Scientifique EPEL, PSE-B 1 ; 1015 Lausanne
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: Keine Daten